Miljana Tanic

Employment

• UCL Cancer Institute Senior Honorary Research Fellow
  2019 - Present
• Institute for Oncology and Radiology of Serbia (IORS) Principal Research Fellow
  2019 - Present
• Aarhus University Hospital Visiting scientist –Research Associate
  2017 - 2017
• UCL Cancer Institute Marie-Sklodowska Curie Research Fellow
  2015 - 2018
• Institute for Oncology and Radiology of Serbia Research Associate
  2012 - 2015
• Columbia University Irving Medical Center Visiting scientist – PT Research Associate
  2011 - 2011
• Centro Nacional de Investigaciones Oncológicas (CNIO) PhD student
  2008 - 2012
• Institute for Molecular Genetics and Genetic Engineering (IMGGE) Undergraduate research volunteer
  2008 - 2008
• Faculty of Biology, University of Belgrade Undergraduate research volunteer
  2007 - 2008
• Spanish National Cancer Research Centre Summer laboratory training
  2007 - 2007

Education

• Universidad Autónoma de Madrid PhD
  2009 - 2012
• Universidad Autónoma de Madrid MSc
  2008 - 2009
• University of Belgrade Faculty of Biology Diploma
  2003 - 2008

Projects & Funding

Projects & funding information is unavailable.

Publications (81)

• The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC
  Cells 2026 DOI: 10.3390/cells15030277
  +Save
• Validation of LOH-Germline Inference Calculator of Variant Origin on Real-World Data of Prevalence of Germline and Somatic BRCA1/2 Mutations in High-Grade Serous Ovarian Cancer in Serbia
  JCO Precision Oncology 2026 DOI: 10.1200/PO-25-00819
  +Save
• DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.
  Nature genetics 2025 DOI: 10.1038/s41588-025-02307-x
  +Save
• Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications
  Seminars in Cancer Biology 2025 DOI: 10.1016/j.semcancer.2025.01.003
  +Save
• Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
  Nature Medicine 2025 DOI: 10.1038/s41591-024-03216-y
  +Save
• Isolation of extracellular vesicles from pleural effusion of patients with lung cancer for downstream application in the clinical setting
  2025 DOI: 10.64898/2025.11.28.25341238
  +Save
• Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
  Nature Communications 2024 DOI: 10.1038/s41467-024-47547-3
  +Save
• The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
  Nature Cancer 2024 DOI: 10.1038/s43018-023-00694-w
  +Save
• Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
  Nature Communications 2024 DOI: 10.1038/s41467-024-47606-9
  +Save
• MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
  Nature Genetics 2024 DOI: 10.1038/s41588-024-01883-8
  +Save